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Abstract
Urinary tract infections are the second most common infectious disease in humans and are predominantly caused by
uropathogenic E. coli (UPEC). A majority of UPEC isolates express the type 1 pilus adhesin, FimH, and cell culture and murine
studies demonstrate that FimH is involved in invasion and apoptosis of urothelial cells. FimH initiates bladder pathology by
binding to the uroplakin receptor complex, but the subsequent events mediating pathogenesis have not been fully
characterized. We report a hitherto undiscovered signaling role for the UPIIIa protein, the only major uroplakin with a
potential cytoplasmic signaling domain, in bacterial invasion and apoptosis. In response to FimH adhesin binding, the UPIIIa
cytoplasmic tail undergoes phosphorylation on a specific threonine residue by casein kinase II, followed by an elevation of
intracellular calcium. Pharmacological inhibition of these signaling events abrogates bacterial invasion and urothelial
apoptosis in vitro and in vivo. Our studies suggest that bacteria-induced UPIIIa signaling is a critical mediator of bladder
responses to insult by uropathogenic E. coli.
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Introduction
Urinary tract infections (UTIs) are the second most common
infectious disease in humans, following respiratory tract infections.
Approximately 90% of community-acquired UTIs are caused by
uropathogenic E. coli (UPEC) [1]. The type 1 pilus is the most
common UPEC virulence factor; present in over 90% of clinical
UPEC isolates and is required to establish cystitis [2,3,4]. Type 1
pili mediate attachment to host cells by virtue of the adhesin
protein FimH that occupies the pilus tip [5]. FimH possesses a
lectin activity specific for mannosylated proteins that maintains
bacterial attachment to the urothelium during urine voiding [6].
Following attachment type-1 pili promote bacterial invasion of
urothelial cells, thereby contributing to the formation of
intracellular bacterial communities (IBCs) [7,8]. Host cell actin
reorganization, PI3-kinase activation, and host protein tyrosine
phosphorylation have all been associated with this invasion process
in cell culture models [7]. Recent studies employing both cell
culture and murine UTI models suggest that UPEC also
commandeer the constitutive endocytic/exocytic machinery of
urothelial cells early during infection, where bacteria reside in
Rab27b/CD63-positive fusiform vesicles [9]. Invasive bacteria can
then exploit the cAMP-regulated exocytic process to re-enter the
bladder lumen during bladder distension.
Urothelium responds to UPEC insult by secreting inflammatory
cytokines and chemokines. IL-6 and IL-8 are detectable in UTI
patient urine, and murine UTI studies show that the recruitment
of neutrophils mediates bacterial clearance by phagocytosis
(reviewed in [10]). Superficial urothelial cells also undergo rapid
apoptosis and are exfoliated into the lumen of the bladder in
murine UTI studies, presumably as a host defense mechanism that
contributes to bacterial clearance by purging tissue-associated
bacteria during voiding [10]. This urothelial apoptotic process is
dependent upon the bacterial expression of type 1 pili since its
FimH activates classical extrinsic and intrinsic apoptotic cascades
[11,12,13]. Despite our increased understanding of FimH-induced
UPEC invasion and urothelial apoptosis, the signal transducer and
downstream second messenger that mediate these two critical
events is currently unknown.
The bladder urothelium is a stratified epithelium with a
superficial layer of ‘‘umbrella’’ cells that are characterized by a
highly specialized apical plasma membrane, the asymmetric unit
membrane (AUM). This unique membrane structure is comprised
mainly of four integral membrane proteins, the uroplakins (UPs)
Ia, Ib, II and IIIa, [14,15,16,17,18]. The AUM is a component of
the permeability barrier that protects underlying tissues from
noxious components of urine because UPIIIa knockout mice
exhibit both altered AUM structure and defective barrier function
[19]. In addition to their roles in AUM structure, UPIa plays an
important role in UPEC pathogenesis by serving as the receptor
for FimH [20,21,22]. UPII and UPIIIa are type-1 transmembrane
proteins that undergo obligatory heterodimerization with UPIa
and UPIb, respectively, during transport to the apical cell surface
[23]. Of the four major uroplakins, UPIIIa alone is predicted to
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signal transducer [17].
Activation of host signal transduction cascades by bacterial
attachment is a well-recognized consequence of host-pathogen
interactions [24], and immediate urothelial signaling events are
associated with UPEC invasion and urothelial cell apoptosis
[25,26]. Recent evidence suggests a possible signaling function for
human uroplakins because xUPIII contributes to Xenopus sperm-
egg fusion [27]. The xUPIII cytoplasmic tail was shown to
undergo phosphorylation on a tyrosine residue and result in Src
kinase-dependent egg activation [27,28,29]. This raises the
possibility that mammalian UPIIIa also plays a signaling role in
the bladder, in addition to its participation in forming the AUM
permeability barrier. We hypothesized that human UPIIIa
transduces urothelial signals that mediate UPEC pathogenesis.
Here, we report a signaling role for the UPIIIa in bacterial
invasion of urothelial cells and in UPEC-induced urothelial cell
apoptosis. FimH induces phosphorylation of threonine-244 on the
UPIIIa cytoplasmic tail by casein kinase II, followed by an increase
in intracellular calcium concentration. Pharmacologic inhibition of
these events abrogates bacterial invasion and apoptosis both in vitro
and in vivo. Our studies suggest that bacteria-induced UPIIIa
signaling is a critical mediator of the pathogenic cascade induced
in the host cell and identify a novel therapeutic target for
intervention in UTI pathogenesis.
Results
Bacterial FimH interacts with the uroplakin receptor
complex in cultured human urothelial cells
In bladder urothelial cells, uroplakins are expressed at the cell
surface and interact with bacterial FimH during UPEC patho-
genesis. We examined the expression of uroplakins in cultures of
PD07i cells, an immortalized normal human urothelial cell line
that is competent to undergo TNF-induced apoptosis [30,31]. We
sought to confirm that uroplakins are expressed in PD07i cells at
the cell surface and that purified FimCH, recombinant FimH in
complex with the FimC chaperone [32], interacts with surface-
expressed uroplakin receptors. For this purpose we derived
affinity-purified uroplakin antibodies that specifically recognize
uroplakin proteins of human origin (Figure 1A, see Figure S1A for
optimization of double staining immunofluorescence using these
antisera). Under differentiation-inducing conditions that induce
robust uroplakin expression [33], these antibodies detected
punctate cell surface expression of human UP1a, UP1b, UPII
and UPIIIa in PD07i cells (Figures 1B–1E). UPIa/UPII and
UPIb/UPIIIa were shown to co-localize on the PDO7i apical cell
surface (Figures 1F–1K). Following treatment of these cells with
biotinylated FimCH (see Figure S1B) we observed distinct co-
localization of FimCH with all the individual uroplakin subunits,
suggesting that FimCH binds to uroplakin complexes containing
all four uroplakins (Figure 2, panels A–L). These results indicate
that PDO7i cells express all four major uroplakin subunits in
complexes that are fully capable of interacting with FimH to
mediate binding and potential downstream signaling events. The
co-localization of FimCH to UPIIIa on the PDO7i cell surface
suggests that FimH binding to the uroplakin receptor complex,
which contains UPIIIa, could potentially lead to signaling events
mediated by the UPIIIa cytoplasmic domain.
Bacterial FimH induces UPIIIa phosphorylation and
elevation in urothelial [Ca
2+]i
Signal transduction cascades in many systems are associated
with the phosphorylation of amino acid residues in the cytoplasmic
domain of transmembrane receptors [34]. To determine whether
UPIIIa functions as a signal transducer in urothelial cells, we
examined UPIIIa phosphorylation upon FimCH binding in
cultures of PD07i cells. PD07i cultures were treated with BSA as
a control protein or with purified FimCH. After immunoprecip-
itation of cell lysates with an anti-UPIIIa antibody, immunoblots
were probed with an anti-phosphothreonine antibody followed by
an anti-UPIIIa antibody to determine loading (Figure 3A).
Treatment with FimCH increased the level of phosphorylated
UPIIIa protein relative to total UPIIIa. In contrast, probing of
immunoblots with an anti-phosphotyrosine antibody did not
reveal any UPIIIa phosphorylation in response to FimCH (data
not shown). UPIIIa phosphorylation was also detected in response
to exposure of PD07i cultures to UPEC strain NU14 followed by
probing with an anti-phosphothreonine antibody (Figure S2).
These results indicate that FimCH binding leads to UPIIIa
threonine phosphorylation and are consistent with a possible role
for UPIIIa as a transducer of UPEC-induced signals.
Intracellular calcium ([Ca
2+]i) elevation is a common signaling
mechanism downstream of many receptors. Since others and we
have previously described [Ca
2+]i elevation during infection with
UPEC in culture [11,25], we examined whether FimCH binding
contributes to an elevation of the intracellular calcium level in
urothelial cells. FimCH induced a transient [Ca
2+]i increase
(Figure 3B) within approximately 40 seconds of treatment of
PD07i cultures. The FimCH-induced [Ca
2+]i increase was
attenuated in minimal calcium medium, but the increase was
largely restored by the addition of calcium to the assay medium
(Figure 3C, compare with 3B). We next examined whether the
[Ca
2+]i response was dependent on FimCH binding to mannosy-
lated proteins on urothelial cells. Inhibition of FimCH-induced
[Ca
2+]i elevation was achieved upon pre-incubation of FimCH
with a-D-mannopyranoside but not D-glucose (Figure 3D),
thereby establishing the specificity of the FimCH-induced effects.
To identify whether the calcium mobilized by FimCH was derived
from an intracellular or extracellular pool, FimCH-induced
[Ca
2+]i increase was measured in the presence pharmacological
inhibitors selective for specific [Ca
2+] pools. Calcium elevation was
significantly inhibited by BAPTA and EGTA, intra- and
extracellular chelators of calcium, respectively, suggesting a role
Author Summary
Urinary tract infections (UTI) are the second most common
infectious disease in humans and are predominantly
caused by uropathogenic E. coli (UPEC). In vitro and in
vivo studies have demonstrated that UPEC induce several
responses in the bladder, including inflammation, rapid
onset of bladder cell death, and bacterial invasion of
bladder cells. This last event, invasion, is now also thought
to underlie recurrent UTI. Although members of the
highly-expressed ‘‘uroplakin’’ proteins serve as bladder
receptors for UPEC binding, it was unclear how UPEC
binding to uroplakin receptors caused signals within
bladder cells that mediate rapid cell death and bacterial
invasion. Here, we show that another uroplakin, uroplakin
III, which is associated with the receptor transduces signals
within the cell in response to UPEC binding. UPEC causes
elevated calcium within bladder cells, and this elevation
requires phosphorylation of uroplakin III by a specific
kinase. Blocking these events blocks both bladder cell
death and bacterial invasion of bladder cells by UPEC.
Thus, uroplakin III is the mediator of key events in UTI
pathogenesis.
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elevation (Figure 3E; P,0.01). An inhibitor of the inositol-
triphosphate (IP3)-gated intracellular calcium channel, 2-ami-
noethoxydiphenyl borate (2-APB), also significantly inhibited the
calcium transient (P,0.05), while the L-type calcium channel
blocker nifidipine (Ndp) had no effect (Figure 3E). These results
Figure 1. Localization of surface-expressed uroplakins on PD07i cells. (A) 0.1 ug of bovine (lane 1, 3, 5, 7) and human (lane 2, 4, 6, 8) AUM
proteins were resolved on 17% SDS-PAGE and transferred onto a nitrocellulose membrane, and detected with monospecific rabbit antisera against Ia
(lane 1, 2), Ib (lane 3, 4), II (lane 5, 6), and IIIa (lane 7, 8). All the uroplakins antibodies are monospecific to a single uroplakin band in both bovine and
human AUM. The surface expression of uroplakins on PD07i cells were detected using immunofluorescent staining using anti-uroplakins Ia (B), Ib (C),
II (D) and IIIa (E) followed with Alexa Fluor 488-conjugated donkey anti-rabbit IgG. Propidium iodide (red) was used to stain nuclei (B–E). Double
staining of uroplakins Ia (F) / II (G) / merge (H), and Ib (I) / IIIa (J) / merge (K) showed co-localization of uroplakins on the apical surface of PD07i cells.
Arrows mark the co-localization of surface-expressed uroplakins (F–K).
doi:10.1371/journal.ppat.1000415.g001
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induced calcium elevation. Extracellular calcium also contributes
to FimCH-induced transients, but the precise mechanism of
calcium influx is unclear.
To examine the role of UPIIIa in mediating calcium elevation,
we used RNA interference to create a urothelial cell line with
reduced expression of UPIIIa mRNA and protein (PD07siUPIII)
[35]. Under differentiation-inducing conditions that induce
Figure 3. FimH induces UPIIIa phosphorylation and intracellular calcium elevation. (A) PD07i cells were stimulated with either 10 mg/ml
FimCH or 10 mg/ml BSA for 30 minutes, and UPIIIa was immunoprecipitated from 100 mg cell extract with anti-UPIII antibody. Following
electrophoresis and blotting, immunoprecipitated proteins were probed with an anti-phosphothreonine antibody (P-Thr). Blots were subsequently
re-probed with an anti-UPIII antibody to determine total protein loading (UP3) (B) PD07i cultures were loaded with 5 mM Fura-2 and imaged for
5 minutes at 340 nm and 380 nm using real-time video fluorescence microscopy. FimCH (10 mg/ml) was added after establishing baseline Ca
2+
concentrations collection for 1 min (arrow). The trace is the mean of a representative experiment of three replicates. (C) Extracellular Ca
2+ is required
for FimCH-induced urothelial Ca
2+ elevation. PD07i cells were loaded with 5 mM Fura-2 and imaged for 10 minutes in nominal Ca
2+-free medium.
Cells were then exposed to 10 mg/ml FimCH, imaged for 5 minutes followed by addition of Ca
2+ to a final concentration of 2.5 mM to the buffer
solution and data were acquired for another 5 min. Baseline Ca
2+ concentration is represented by the dotted line. The trace is the mean of a
representative experiment of three replicates. (D) FimCH-induced [Ca
2+]i elevation is inhibited by pre-incubation with a-D-mannoside. FimCH was
pre-incubated for 30 minutes with 25 mM a-D-mannoside or D-glucose. PDO7i cells loaded with 5 mM Fluo-4 AM were treated with 10 mg/ml of the
pre-incubated FimCH. PDO7i cells were imaged at 488 nm using real-time video fluorescence microscopy and maximal fluorescence after FimCH
treatment was subtracted from baseline. (E) Chelating intracellular or extracellular Ca
2+ inhibits elevation of FimCH-induced [Ca
2+]i. PD07i cells loaded
with 5 mM Fura-2 were pre-incubated with 10 mM BAPTA-AM, 4 mM EGTA, 60 mM 2-APB, 10 mM nifidepine (Ndp), or equivalent amounts of DMSO for
30 minutes, followed by washing and exposure to 10 mg/ml FimCH. Maximal [Ca
2+]i was subtracted from baseline [Ca
2+]i. Statistical significance is
indicated at *p,0.05 or **p,0.001 and data are represented as mean6SEM. (F) Knockdown of UPIIIa expression inhibits FimCH-induced Ca
2+
elevation. Control cells (PDO7isiTNFR2) or PD07isiUPIII cells were loaded with Fura-2 and imaged upon addition of 10 mg/ml FimCH followed by post-
acquisition analysis. All experiments were repeated at least three times, and statistical significance is indicated at *p,0.05 and data are represented as
mean6SEM.
doi:10.1371/journal.ppat.1000415.g003
Figure 2. Co-localization of uroplakins and FimH binding sites on PD07i cell surface. The surface-expressed uroplakins on PD07i cells were
detected using antisera against individual uroplakins Ia (B), Ib (E), II (H), and IIIa (K), followed by Alexa Fluor 594-conjugated donkey anti-rabbit IgG;
while FimH was localized using biotinylated FimH/C complex, followed with FITC-conjugated streptavidin (A, D, G, J). Arrows mark the co-localization
of surface-expressed uroplakins and FimH binding sties (A–L).
doi:10.1371/journal.ppat.1000415.g002
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cultures was reduced to less than 1% of the parental PD07i
cultures [35]. PD07siUPIII cells exhibited significantly lower
FimCH-induced calcium elevation relative to a control PD07i cell
line that stably expresses siRNAs against a control protein
(Figure 3F; P,0.05). These data suggest that UPIIIa is involved
in mediating FimH-induced calcium elevation in urothelial cells.
Taken together, these findings suggest that the events initiated
upon FimCH binding of urothelial cells include signal transduc-
tion through UPIIIa by phosphorylation of UPIIIa threonine(s)
and elevation of the intracellular second messenger calcium.
FimCH-induced [Ca
2+]i elevation requires UPIIIa
threonine 244
The UPIIIa cytoplasmic domain consists of ,52 amino acids
that harbor multiple potential phosphorylation sites (Figure 4A).
We examined the involvement of threonine-244 (T244), and serine-
282 (S282), residues predicted to be part of casein kinase II (CK2)
and protein kinase C (PKC) phosphorylation motifs, in FimCH-
induced calcium elevation. We also examined the involvement of
tyrosine-266 (Y266), a potential phosphorylation site homologous
to tyrosine-249 previously implicated in UPIII signaling in Xenopus
oocytes. Specific mutations in a UPIIIa cDNA were generated that
converted the potential phosphorylation sites to either glutamic
acid or alanine, to mimic constitutive phosphorylation or block
phosphorylation, respectively. Similarly, Y266 was mutated to
phenylalanine to block phosphorylation. We utilized COS-7 cells
for heterologous expression of the mutated UPIIIa variants since
they lack endogenous UPIIIa expression [36]. Recombinant
adenoviruses encoding the UPIIIa proteins were used to co-infect
COS-7 cells along with an adenovirus encoding UPIb which, in
culture, mainly harbor high mannose glycan [19,23] that should
therefore be able to serve as FimCH receptor. Immmunofluores-
cence studies were used to confirm heterologous surface uroplakin
expression with recombinant adenoviruses. An affinity-purified
antibody to UPIIIa, P3, was used in this experiment (see Figure S3
for specificity). Although infection of COS-7 cells with recombi-
nant adenoviruses encoding either UPIIIa alone did not result in
detectable uroplakin expression, co-infection of COS-7 cells with
UPIb and UPIIIa viruses resulted in a significant surface UPIIIa
expression detectable using either AU1 or P3 antibodies (Figure 4B
iv–viii) [19,23]. Like wild type UPIIIa, infection of COS-7 cells
with recombinant adenoviruses encoding UPIIIa site-directed
mutants also resulted in detectable UPIIIa surface staining when
co-expressed with UPIb (Figure S4).
We next examined the ability of wild-type and mutated UPIIIa
variants to mediate [Ca
2+]i elevation in response to FimCH.
Following exposure to FimCH, cultures co-infected with wild type
UPIIIa and UPIb viruses exhibited increased [Ca
2+]i, whereas
[Ca
2+]i elevation was not observed in cultures co-infected with
UPIb and LacZ viruses, (Figures 4C and 4D). The kinetics of
FimCH-induced [Ca
2+]i increase in COS-7 cells were slightly
delayed and sustained compared to stimulation of PD07i cultures
(compare Figures 4D and 3B), perhaps due to the expression of
additional uroplakins in PD07i cultures or other urothelial-specific
factors absent in the COS-7 heterologous expression system.
Nonetheless, finding UPIIIa-associated, FimCH-induced [Ca
2+]i
increases demonstrates the utility of COS-7 cells for uroplakin
structure/function studies. Expression of the phosphorylation-
deficient T244A UPIIIa variant was associated with a diminished
FimCH-induced calcium elevation in COS-7 cells (Figure 4D-i,
p,0.05), but the S282A and the Y266F variants retained
responsiveness to FimCH (Figure 4D-ii and -iii), suggesting a
specific requirement for T244 phosphorylation as a mediator
UPIIIa signaling. The S282A variant (Figure 4D-ii) had an
unexpected stimulatory effect on [Ca
2+]i elevation in response to
FimCH while the constitutively phosphorylated T244E mutation
reversed the inhibitory effect observed with the alanine replace-
ment (Figure 4C and 4D). These findings suggest that FimCH-
induced phosphorylation of UPIIIa on T244 is important for
mediating [Ca
2+]i elevation in urothelial cells.
UPIIIa cytoplasmic tail phosphorylation is mediated by
casein kinase II
Because T244 of the UPIIIa C-terminus resides within a
predicted casein kinase II (CK2) phosphorylation motif, we
examined the potential role of CK2 in UPIIIa signaling. We
performed an in vitro kinase assay with recombinant CK2 and a
fusion protein of the C-terminal 52 amino acids of UPIIIa with
glutathione-S-transferase (UP3C-GST) as substrate. UP3C-GST
underwent dose-dependent phosphorylation that was completely
blocked by a pharmacological inhibitor of CK2, 4,5,6,7-tetra-
bromobenzotriazole (TBB), (Figure 5A). Since UP3C-GST serves
as a CK2 substrate in cell-free system, we next examined the
potential role of CK2 in FimCH-induced calcium elevation. While
the vehicle had no effect on [Ca
2+]i elevation in PD07i cultures
stimulated with FimCH, TBB significantly abrogated FimCH-
induced [Ca
2+]i elevation (Figure 5B; P,0.01). To confirm the
role of CK2 in modulation of FimH-induced signaling, we also
examined the effects of TBB on uroplakin signaling in COS-7 cells
expressing UPIIIa variants. TBB significantly reduced the [Ca
2+]i
elevation induced by FimCH treatment of COS-7 cultures
expressing wild type UPIIIa (co-transfected with UPIb;
Figure 5C; P,0.05), and TBB significantly enhanced the calcium
response in cultures expressing the T244A variant. To confirm the
role for CK2 in FimH-induced calcium elevation, we utilized
RNA interference to knockdown expression of CK2 in PDO7i
cells. CK2 mRNA expression in PDO7i cultures transfected with
CK2 siRNA was decreased by 75% compared with non-specific
siRNA transfection (Figure S6, p,0.01). We then found that
FimCH induced a significantly attenuated [Ca
2+]i elevation in
CK2-silenced cells compared with the controls (Figure 5D). These
results indicate that CK2 phosphorylates UPIIIa and mediates the
FimCH-induced [Ca
2+]i elevation in urothelial cells.
CK2 mediates urothelial invasion by UPEC invasion
Previous reports demonstrate that UPEC strains invade
urothelial cells in vitro and in vivo, and FimH is required for these
processes [7,13,37]. We examined UPEC invasion of PD07i
urothelial cells by the archetypal cystitis strain NU14 [38].
Intracellular NU14 were distinguishable from extracellular
NU14 by fluorescence microscopy, confirming that PD07i cultures
are useful for examining UPEC invasion of urothelial cells
(Figure 6A). Consistent with previous reports, the FimH-deficient
isogenic mutant of NU14-1 [38] was severely defective in both
adherence and invasion of PD07i cells relative to wild-type NU14
(Figures 6B and 6C). To investigate the role of UPIIIa signaling in
UPEC invasion, we utilized 5637 cells, a human carcinoma-
derived urothelial cell line, to over-express wild-type and mutated
UPIIIa. 5637 cells have been previously shown to support UPEC
invasion through a3 and b1 integrins [39]. COS-7 was not utilized
for these invasion studies because preliminary experiments showed
that COS-7 cells supported high levels of basal NU14 invasion
(data not shown). Since the 5637 cell line has constitutive
expression of uroplakin proteins including the UPIIIa and its
partner UPIb, adenoviral mediated overexpression of the wild-
type or mutant UPIIIa alone was used to study their effects on
UPEC invasion. Bacterial adherence to cells expressing the wild-
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2+ elevation involves T244 mediated signaling. (A) The cytoplasmic tail of UPIIIa comprises of 52 amino acids
with two predicted CK2 and one protein kinase C phosphorylation motif (underlined). T244 and S282 (indicated by asterisks) were mutated to A/E and
Y266 (indicated by pound) to F to identify the phosphorylation site involved in FimCH-mediated Ca
2+ signaling. (B) Mouse bladder sections were
stained with P3 antibodies (red, i; see text) and AU1 antibody (green, ii), and the images were merged to confirm specificity (iii). COS-7 cells were
infected with UPIb (iv) or UPIIIa adenovirus (v) and stained for UPIIIa protein with P3 antibodies. COS-7 cells co-infected with UPIb and UPIIIa viruses
were stained with P3 antibodies (red, vi and vii) or P3 and AU1 (viii). Arrows indicate staining consistent with surface expression (vi–viii). Arrows
indicate staining consistent with surface expression (vi–viii). (C) T244 mediates FimCH-induced Ca
2+ elevation. Data acquired as in (D) were subject to
post–acquisition analysis by subtracting maximal Ca
2+ elevation following addition of 10 mg/ml FimCH from baseline Ca
2+ concentration in COS-7
cultures. COS-7 cultures were previously infected with recombinant adenoviruses encoding UPIb and either wild type UPIIIa or UPIIIa variants or LacZ.
At 24 h post-infection, traces of FimCH-induced Ca
2+ elevation were acquired and reveal a requirement for T244 mediated signaling. (D)
Representative traces are shown for T244 (i), S282(ii) and T266(iii) along with WT. All experiments were repeated three or more times, and statistical
significance is indicated at *p,0.05 or **p,0.001 and data are represented as mean6SEM.
doi:10.1371/journal.ppat.1000415.g004
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shown). Wild type UPIIIa expression in 5637 cells significantly
increased NU14 invasion relative to control cultures infected with
control virus (Figure 6D; P,0.05). In contrast, expression of the
UPIIIa T244E variant resulted in a much lower NU14 invasion
than the wild type UPIIIa (P,0.05), consistent with a role for T244
in bacterial invasion.
To examine the role of CK2 in UPEC invasion, we quantified
NU14 invasion in PD07i cultures in the presence of the CK2
inhibitor TBB. TBB had no effect on NU14 adherence to PDO7i
cells (Figure 6E) but significantly decreased NU14 invasion
(Figure 6F; P,0.01), yielding results comparable to treatment
with the PI3-kinase inhibitor wortmannin, a known inhibitor of
NU14 invasion [7]. To confirm the role of CK2 in NU14 invasion
of urothelial cells, we used RNA interference to knockdown the
expression of CK2. Knockdown of CK2 expression had no effect
on the adherence of NU14 to PDO7i (Figure 6G) but significantly
inhibited NU14 invasion when compared with a non-specific
siRNA control (Figure 6H; p,0.05). These results indicate a role
for CK2 in NU14 invasion of urothelial cells.
To determine the role of CK2 in UPEC invasion in vivo,w e
modified a murine UTI model [40]. Female C57BL/6 mice were
instilled via transurethral catheter with 10 ml of NU14 bacterial
suspensions at a concentration of 10
10 CFU/ml plus either TBB
or vehicle. After 2 hours, bladders were removed, opened, and
incubated with gentamicin to kill extracellular bacteria before
plating the tissue homogenates. Invasive NU14 levels were
significantly reduced in the TBB-treated bladders relative to
bladders of mice treated with vehicle alone (Figure 6I; P,0.05).
These data suggest that CK2 is an important mediator of UPEC
pathogenesis at the level of urothelial invasion.
UPEC-induced apoptosis is mediated by UPIIIa signaling
Since FimH is known to induce urothelial cell death [11,12], we
examined the potential involvement of UPIIIa signaling in
apoptosis. We first confirmed the role of FimH by demonstrating
that NU14 induces a higher level of caspase activation, than the
FimH-deficient strain NU14-1, in a PD07i cell line expressing a
luciferase control plasmid [30] (Figure 7A; P,0.05). We next
examined the role of UPIIIa by examining caspase activation in
PD07siUPIII, an UPIIIa-deficient cell line. PD07siUPIII showed
diminished caspase activation in response to NU14 when
compared with control PD07i cultures, thereby confirming our
previous observation that FimH-mediated urothelial cell death
correlates with UPIIIa expression [35]. We also examined annexin
V staining as an early marker of urothelial apoptosis [12,30]. We
found that annexin V staining was significantly more prevalent in
control cultures than PD07siUPIII cultures (Figure 7B; P,0.05).
Similarly, parent PD07i cultures treated with FimCH in the
presence of the CK2 inhibitor TBB exhibited reduced annexin V
staining, whereas FimCH treatment in the presence of vehicle
were stained in significantly larger numbers (Figure 7C). We also
examined FimCH-induced apoptosis following bacterial infection
of organotypic raft cultures that recapitulate the urothelial
differentiation program [31]. Organotypic cultures of PD07i cells
exhibited FimH-dependent apoptosis, as indicated by TUNEL
staining in NU14-treated cultures that was absent in NU14-1-
treated cultures (Figure 7D). However, PD07siUPIII organotypic
cultures did not undergo FimH-dependent apoptosis. Together,
these data suggest that FimH-induced urothelial apoptosis is
mediated by both UPIIIa and CK2 signaling.
We next examined the role of CK2 in UPEC-induced urothelial
apoptosis in vivo by infecting mice with NU14 in the presence or
absence of TBB and then detecting apoptosis by TUNEL staining
[13]. TUNEL staining of bladder sections revealed foci of cells in
the superficial layer of the bladder of control animals instilled with
an NU14 suspension, but this was inhibited by TBB (Figure 7E,
panels i and ii).
To determine whether UPIIIa signaling affected urothelial
responses other than those involved in bacterial invasion and
apoptosis, we examined TLR-dependent urothelial inflammatory
responses in vitro following UPEC infection [41]. UPEC infection
as well as treatment with the pro-inflammatory cytokine IL-1b
induced similar level of CXCL-8 secretion in both PD07siTNFR2
and PD07siUPIIIa cultures (Figure S5). These results suggest that
UPIIIa signaling is not required for urothelial inflammatory
responses. In addition, in vivo murine UTI infection with NU14
Figure 5. CK2 phosphorylates UPIIIa cytoplasmic domain and is required for FimCH-induced Ca
2+ elevation. (A) UPIIIa cytoplasmic
domain is phosphorylated by CK2 in vitro. Recombinant human CK2 (50 U) exhibited autophosphorylation (lane 1) that was blocked by 10 mM of the
CK2 inhibitor TBB (lane 2). A fusion protein of the C-terminal domain of uroplakin IIIa with glutathione-S-transferase (UP3C-GST, arrow) served as a
concentration-dependent substrate for phosphorylation by CK2 (lanes 3–6 containing 0.01 mg, 0.10 mg, 0.25 mg, or 1.00 mg UP3C-GST, respectively).
CK2-mediated phosphorylation of 0.10 mg UP3C-GST was inhibited by TBB (lane 7). (B) Inhibition of CK2 abrogates FimCH-induced calcium elevation.
Urothelial cells were loaded with Fura-2 AM and pretreated with 10 mM TBB (or equivalent concentration of vehicle (DMSO)) for 30 minutes, treated
with FimCH and followed by imaging. Statistical significance is indicated at *p,0.05 and data are represented as mean6SEM. (C) COS-7 cells were
infected with recombinant adenoviruses and FimCH-induced calcium was quantified as in (B) in the presence or absence of TBB. (D) RNA silencing of
CK2 inhibits FimCH-induced calcium elevation in urothelial cells. PD07i cells transfected with siCK2 showed significantly reduced elevation in calcium
as measured by the change in Fura-2 340/380 ratio compared to transfection with negative control siRNA. All experiments were repeated three or
more times, and statistical significance is indicated by *p,0.05, **p,0.01.
doi:10.1371/journal.ppat.1000415.g005
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NU14-GFP (MOI 100; green) and stained for extracellular E. coli (red). (B) FimH mediates UPEC adherence to PD07i cells. Urothelial cells were infected
with NU14 or NU14-1 at an MOI of 10, and infection proceeded for 2 h followed by washing. Cell lysates were plated on LB-agar to determine
adherent bacteria. (C) FimH promotes UPEC invasion. PD07i cells were infected as above, washed and incubated in culture medium with 100 mg/ml
gentamicin for 30 minutes followed cell lysis and plating onto agar. (D) NU14 invades 5637 cells infected with UPIIIa variants. Adenoviruses
expressing various UPIIIa phosphorylation variants were used to infect 5637 cells followed by quantification of invasive bacteria. Inhibition of CK2
abrogates UPEC invasion but not adherence to urothelial cells (E&F). Adherence and invasion assays were performed as above with some
modifications. Urothelial cells were infected with NU14 in the presence of 10 mM TBB, 1 mM wortmannin or vehicle control at an MOI of 100, medium
was replaced after 1 hour with inhibitor-free media and infection was allowed to proceed for a further 1 hour followed by quantification of
adherence and invasion as above. (G) Inhibition of CK2 using transfected siRNA does not affect adherence of NU14 to urothelial cells but reduces
bacterial invasion of the bladder (H). In vivo TBB administration significantly reduced NU14 invasion of the bladder in female C57BL/6 mice (I). Mice
were catheterized transurethrally with 10
8 CFU of NU14 bacteria in PBS with TBB (10 mM) or a vehicle control (DMSO). Infection was allowed to
proceed for 2 h followed by bladder removal and incubation in PBS with 100 mg/ml gentamicin ex vivo for 30 minutes at 37uC. Bladders were washed
in antibiotic-free PBS and homogenized for quantification of bacterial colonization. With the exception of (I), all experiments were repeated threeo r
more times, results are expressed as mean6SEM with statistical significance indicated at *p,0.05.
doi:10.1371/journal.ppat.1000415.g006
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with vehicle or the CK2 inhibitor TBB (Figure 7E, panels iii and
iv). Taken together, our data suggest that UPIIIa and CK2
specifically mediate two key events in UTI pathogenesis, UPEC
invasion of urothelial cells and urothelial apoptosis.
Discussion
Uroplakins are critical components of the AUM that provide
the bladder permeability barrier, yet AUM dynamics suggest the
ability to modulate urothelial cell signaling [42]. The discovery of
bovine UPIa as the receptor for FimH provided the first evidence
for involvement of uroplakins in UTI pathogenesis [20,22]. These
interactions are presumed to mediate two key UPEC-induced
events observed in cell culture and murine UTI models, namely
rapid urothelial apoptosis and invasion of urothelial cells by UPEC
[7,11,12]. While both events require activation of cell signaling
cascades, the proximal mediator of these cascades has not been
identified. This study provides evidence that UPIIIa is a
membrane-proximal signal transducer of UPEC pathogenesis in
the bladder.
Uroplakins as functional UPEC receptors
Using monospecific antibodies for individual uroplakins, we
showed that UPIa and UPIb co-localized with UPII and UPIIIa,
respectively, in cultured human PD07i urothelial cells (Figure 1).
This result is consistent with our previous finding that individual
uroplakins preferentially form UPIa/UPII and UPIb/UPIIIa
Figure 7. UPIIIa mediates FimH-induced urothelial apoptosis. FimH-induced caspase 3/7 activation requires UPIIIa (A). Caspase 3/7 was
measured in culture extracts by cleavage of fluorogenic substrate. Induction of caspase 3/7 activity by NU14 (MOI 500) was significantly inhibited in
PD07siUPIII cultures (*p,0.05) compared to control, and no induction of caspase 3/7 was detected in response to NU14-1. (B) PD07siTNFR2 cells or
PD07siUPIII cells were treated with 10 mg/ml FimCH for 4 h. Apoptosis was visualized using fluorescent annexin V staining (green) and propidium
iodide (red) staining. Annexin staining was quantified by manual counting of fluorescently labeled cells relative to brightfield images (see Methods).
Annexin-positive cells were significantly reduced in siUPIII cells relative to siTNFR2 cells (p,0.05). (C) In experiments in the presence of inhibitors,
PD07i cells treated with 10 mg/ml FimCH showed reduced annexin staining when treated with the CK2 inhibitor TBB compared to DMSO (p,0.05). (D)
Organotypic raft cultures of PD07i or PD07siUPIII cells were incubated with NU14 or NU14-1 for 4 h at an MOI of 100. After processing, frozen sections
were stained for TUNEL (green) and counterstained with DAPI (blue). Prominent TUNEL staining was induced by NU14 only in PD07i tissue. Images
are representative of staining patterns obtained from TUNEL assay of four different raft cultures. (E) UPEC-induced apoptosis was also assessed in
bladder sections using TUNEL staining (green). In in vivo experiments female C57BL/6 mice were infected with 10
8 NU14 or NU14-1 for 6 hours in the
presence of DMSO (i) or 10 mM TBB (ii). Bladder sections from DMSO treated animals exhibited foci of apoptosis (arrows) that were reduced or absent
in TBB-treated animals. In H&E stained bladder sections from DMSO (iii) and TBB (iv) treated mice, infiltration of large numbers of inflammatory cells
(white arrows) were observed in response to infection with 10
8 NU14 for 2 hours, suggesting an intact innate immune response. Images are of
representative sections and scale bars represent 50 mm. All experiments were repeated two or more times, and statistical significance is indicated at
*p,0.05 and data are represented as mean6SEM.
doi:10.1371/journal.ppat.1000415.g007
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export from the endoplasmic reticulum [23,43,44]. Uroplakins
residing outside the afore-mentioned, preferred heterodimers were
much less colocalized (data not shown). The data reported here are
also consistent with our previous reports: uroplakins in cultured
bovine urothelial cells remain as heterodimers, whereas in normal
urothelium in vivo these uroplakin heterodimers proceed to form
heterotetramers, six of which then form the hexagonal 16-nm
particle [43]. The fact that uroplakin staining appeared punctate
suggests that uroplakins accumulated preferentially on apical
microvilli of PD07i cells (Figures 1 and 2), similar to our previous
observations in cultured bovine urothelial cells [45]. Taken
together, our results establish that human urothelial PD07i cells
express all four major uroplakins primarily as heterodimers.
Previous studies indicate that UPIa is the main UPEC receptor
in normal urothelium, yet data presented here suggest that UPIb
may serve as an alternative FimH receptor in cultured urothelial
cells (Figure 2). Of the four major uroplakins present in mouse
urothelial plaques, we previously showed that UPIa is the only
uroplakin bearing large amounts of high mannose glycan [21].
Consistent with this result, type 1-piliated E. coli or recombinant
FimCH preferentially bound UPIa, and similar results were
obtained with human uroplakins, suggesting that UPIa is the main
UPEC receptor in vivo [20,21,22]. UPIb and UPIIIa harbor mainly
complex sugars [17,18,21]. UPII is unlikely to function as a UPEC
receptor, for proteolytic processing of pro-UPII that harbors three
N-glycosylation sites eliminates those sites from mature UPII [46].
Somewhat unexpectedly, we found here that FimCH co-localized
with all four uroplakins (Figure 2), suggesting that FimH may
interact with either uroplakin Ia/II or Ib/IIIa heterodimers on
PD07i cells. However, this is consistent with previous observations
that heterologous expression of UPIa/UPII and UPIb/UPIIIa
pairs in COS-1 cells resulted in both UPIa and UPIb bearing high
mannose glycans [43]. Together these findings suggest that
uroplakins exist mainly as heterodimers in culture models, and
both UPIa/UPII and UPIb/UPIIIa pairs are functional FimH
receptors. Therefore, while culture models are convenient for
identifying molecular mechanisms of FimH-induced UPIIIa
signals, we also validate these findings in vivo, where UPIa is the
major FimH-receptor (Figures 6 and 7).
FimH-induced uroplakin III signaling
Sperm-egg fusion in Xenopus provided the first evidence for a
signaling role for uroplakins with phosphorylation of the
cytoplasmic tail of xUPIII on Y249 [27]. In contrast to these
results, our data implicate phosphorylation of T244 as a key early
event induced by FimH binding in culture. Indeed, we found that
mutation of hUPIIIa Y266, the homologous position to xUPIII
Y249, did not influence FimH-induced calcium elevation, suggest-
ing that signaling initiated by modification of hUPIIIa Y266 is not
involved in urothelial responses to UPEC. This difference in
phosphorylation site utilization may represent ligand-specific,
species-specific, and/or tissue-specific signaling. We do not
however rule out the possibility that yet-unidentified physiological
ligands induce human UPIIIa phosphorylation on tyrosine
residues using conserved mechanisms comparable to Xenopus.O n
the contrary, we speculate that the presence of multiple putative
phosphorylation sites on the cytoplasmic tail of UPIIIa mediate
responses to diverse stimuli and involvement in multiple biologic
processes, such as fusiform vesicle exocytosis that expands the
AUM surface area during bladder filling [47].
Our findings that UPIb was sufficient for UPIIIa-mediated
responses induced by FimH in COS-7 cells (Figures 4 and 5) is
consistent with the conserved function of complexes containing
tetraspanin proteins. Tetraspanins typically function as transmem-
brane linkers in a complex with other proteins that then transduce
signals [48]. Thus in the case of uroplakin complexes, tetraspanins
function as the ligand binding module (UPIa/UPIb, and UPIII
tranduces FimH-induced signals. The precise mechanism by
which FimH-uroplakin interactions transduce signals across the
highly impermeable urothelial apical membrane remains un-
known. However, Kong and colleagues have recently used cryo-
electron microscopy to show that FimH binding induces gross
conformational changes in the entire uroplakin receptor complex,
including movement of the transmembrane helices to potentially
induce structural changes in the uroplakin cytoplasmic tails
(Xiang-Peng Kong, New York University School of Medicine,
personal communication). These independent results bolster our
hypothesis that FimH-induced changes in the transmembrane
helices of the uroplakin receptor complex mediate the transmem-
brane signal that triggers bacterial invasion and host cell responses.
Uroplakin III signaling in UTI pathogenesis
The finding that UPIIIa signaling initiates [Ca
2+]i elevation has
important implications for UPEC pathogenesis. FimH-mediated
calcium elevation occurs as a result of calcium release from
intracellular stores and by influx from extracellular sources, and
calcium elevation promotes global responses critical to UPEC
pathogenesis including cytokine stimulation, membrane trafficking
and apoptosis [25,49]. The findings here extend our earlier
observations that sustained calcium elevation is associated with
UPEC-induced apoptosis [11] and suggest a role for calcium
signaling in both immediate early host responses and subsequent
events. Our finding that UPIIIa initiates urothelial calcium also
presents a testable hypothesis for the mechanism underlying the
modulation of calcium-dependent exocytosis of fusiform vesicles
during bladder stretch [47].
Approximately 25% of UTI patients suffer recurrent infections,
and invasion of urothelial cells in culture and in mice promotes the
establishment of a drug-resistant UPEC niche that may underlie
recurrent UTIs in humans [37]. The factors required for UPEC
invasion in vitro include expression of type-1 pili, intracellular
signaling events mediated by PI3-kinase, and activation of Rho-
GTPase [50]. In this study, we examined the role of the UPIIIa
signaling in UPEC invasion in vitro and in mice utilizing the CK2
inhibitor TBB, because mutagenesis studies implicated a putative
CK2 site at T244 of the UPIIIa cytoplasmic tail. TBB inhibition of
UPEC invasion suggests that FimH-mediated mechanisms of
invasion in the bladder also rely on UPIIIa and CK2. The UPIIIa
variant T244E, designed to mimic constitutively phosphorylated
UPIIIa, inhibited invasion, while the T244A has no such effect.
Thus, the phosphorylation status of T244 has implications for
UPEC invasion. The absence of correlation between calcium
signaling with the T244 mutants and UPEC invasion may result
from distinct kinetics. Calcium signaling is an early event
occurring within minutes while invasion is measured within hours.
These results suggest that UPIIIa-induced signals may interact
with other signals induced by UPEC binding to modulate UPEC
invasion of urothelial cells. For example, recent studies demon-
strate that UPEC adherence induces cAMP increases via TLR4
signaling, and this increase hinders UPEC invasion [51]. The
salutary effects of TBB on UPEC invasion in vivo suggest CK2 is a
novel therapeutic target for intervention in UTI at the level of
inhibiting UPEC invasion.
It has been postulated that urothelial apoptosis is a host defense
mechanism against UPEC insult, because inhibiting apoptosis in a
murine UTI model was detrimental to bacterial clearance from
the bladder [13]. We previously showed that UPEC-induced
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of intrinsic and extrinsic cell death pathways [11,12]. In this study
we demonstrate that FimH-induced apoptosis is dependent upon
the expression of UPIIIa and is inhibited by abrogation of signals
downstream of UPIIIa. We have also recently shown that
increasing levels of UPIII expression in urothelial cells renders
cells more susceptible to FimCH-dependent apoptosis [35].
Interestingly, UPIIIa expression or signaling does not appear to
be required for urothelial inflammatory responses, suggesting that
UPEC-induced signals emanating from UPIIIa are separate and
unique from simultaneous inflammatory signals mediated by
TLRs. The potential interactions between simultaneous UPEC
activation of both pro-apoptotic and pro-inflammatory pathways is
intriguing but uncharacterized.
We propose a model of UPEC pathogenesis that combines the
known responses to UPEC with the UPIIIa signaling described in
this study (Figure 8). The host response is characterized by events
in distinct kinetic classes representing immediate early signaling
responses, early innate responses, and culminating in late events.
Our findings identify FimH-induced UPIIIa signaling mediated by
Figure 8. Model of UPIIIa mechanisms of UPEC pathogenesis. (A) UTI pathogenesis in the bladder occurs in distinct kinetic phases. Immediate
early host responses include UPIIIa phosphorylation and increased [Ca
2+]i (this study), PI3K activation [7], actin rearrangement [50], and increased
cAMP [51]. Subsequent early host responses include UPEC internalization [7], NFkB-dependent chemokine production and modulation [12], urothelial
apoptotic cascades [11], and bacterial clearance mediated by neutrophils [10]. Late events include adaptive responses that confer protective
immunity [40] and establishment of stable UPEC reservoirs within the urothelium [37]. (B) UPEC interaction with uroplakins leads to phosphorylation
of the UPIIIa cytoplasmic tail by CK2 and the initiation of two signaling cascades. Elevation in intracellular calcium from intra- and extracellular stores
and the associated recruitment of other signaling molecules activates host cell cytoskeletal elements and the endocytosis of UPEC. UPIIIa
phosphorylation activates an unknown signaling intermediate that initiates intrinsic and extrinsic apoptotic cascades. Pro-survival signals initiated by
TLR activation may shift the balance away from UPIIIa-induced pro-apoptotic signals in those cells where UPEC successfully establish stable
intracellular populations.
doi:10.1371/journal.ppat.1000415.g008
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2+]i elevation as the immediate host
responses. These membrane-proximal signals activate two seem-
ingly opposed urothelial outcomes – urothelial invasion by UPEC
and UPEC-induced apoptosis. Bacterial invasion occurs through
activation of the host cytoskeleton and utilization of conserved
endocytic pathways. The demonstration of a role for the
endocytic/exocytic machinery of urothelial fusiform vesicles in
UPEC invasion leads us to speculate that UPEC-mediated UPIIIa
signaling is a bacterial pathogenesis mechanism initiated to
activate the endocytic machinery in urothelial cells, thereby
gaining access to an intracellular sanctuary [9]. Apoptosis,
triggered by an as-yet-unknown signaling intermediate, rids the
host of infection and may be considered part of a robust innate
response. In the event of a successful innate response, the
urothelial cell undergoes apoptosis and is eliminated in the urine.
We postulate that initiation of apoptosis may require a threshold of
UPIIIa signaling that varies from cell-to-cell depending on levels of
UPIIIa expression or expression of other cellular factors. This
scenario is consistent with heterogeneous bladder lesions induced
by UPEC and the recent finding that urothelial cells may derive
from multiple progenitor populations [52]. In the absence of this
robust clearance mechanism, invasive bacteria are likely to
establish stable reservoirs. Successful establishment of this
immune-resistant niche may also require pro-survival TLR signals
that shift the equilibrium away from apoptosis and promote cell
survival. Irrespective of the precise mechanisms, the balance
between pro-survival and pro-apoptotic mechanisms may deter-
mine UPEC pathogenesis in the urinary bladder.
In summary, two critical pathogenic results of UPEC-urothelial
interactions, bacterial invasion and host cell apoptosis, involve
UPIIIa and are associated with CK2 and calcium signaling. This
first description of human UPIIIa as a signal transducer raises
important questions regarding the normal physiological function
of this highly expressed protein in the mammalian urinary
bladder. Determining how UPIIIa-mediated signals interact with
the recently characterized role of TLR4-induced cAMP modula-
tion will illuminate key aspects of both urothelial biology and host-
pathogen interactions in UTIs. Finally, identifying calcium and
CK2 as immediate early host responses to UPEC offers novel
therapeutic targets for intervention in UTIs.
Methods
Mice
Female C57BL/6 mice were obtained as specific-pathogen-free
from Jackson Laboratories (Bar Harbor) and housed in North-
western University’s Center for Comparative Medicine. After a 1-
week acclimatization, 6- to 10-week old mice were anesthetized
with isoflurane and inoculated by transurethral catheter with 10
8
CFU E coli in 10 ml to minimize reflux to the kidneys [53]. All
experiments were conducted using protocols approved by the
Animal Care and Use Committee of Northwestern.
Bacterial strains
NU14 was obtained from the urine of a cystitis patient, and
NU14-1 lacks functional type 1 pili [38]. Bacteria were cultured in
static Luria broth at 37uC to promote type 1 pilus expression [54]
that was confirmed by mannose-sensitive haemagglutination
[55,56]. For in vitro infections, bacteria were centrifuged and
washed once in cold PBS. Bacteria were resuspended in culture
medium at the appropriate multiplicity of infection (MOI).
Bacterial preparation for in vivo studies was performed as
previously described [40]. FimCH, a stabilized form of FimH in
complex with the FimC chaperonin, was a kind gift from Dr.
Hultgren.
Biotinylation of FimH/C complex
Briefly, 1 mg of FimH/C in 1 ml 50 mM Na2CO3-NaHCO3
(pH 9.0) was mixed with 50 ml sulfo-NHS-biotin (1 mg/ml; Cat#
21217, Pierce Chemical, Rockford, IL) freshly dissolved in water.
The mixture was left on ice for 2 hours, and the buffer was
changed to Tris-buffered saline (TBS) (150 mM NaCl, 50 mM
Tris-HCl, pH 7.5) through ultrafiltration (Centricon, 10 k-Da
cutoff, Millipore, Bedford, MA) to remove the free biotin [22].
Cell culture
PD07i cells are an immortalized human urothelial cell line
previously established by infection of normal human urothelial
cells (obtained by dissociation of pediatric bladder) with a
retrovirus encoding E6E7 of HPV type 16 [30]. PD07i cells were
maintained in EpiLife medium (Invitrogen). PD07i cells were used
to establish a stable cell line in which UPIIIa expression was
blocked using short hairpin RNA (shRNA) specific for UPIIIa and
designated as PD07isiUPIII (Clone V2HS_95009, OpenBiosys-
tems). As a control for the retroviral vector used in these studies,
PD07i cells expressing shRNA targeting TNF receptor 2
designated PD07isiTNFR2 were also employed to demonstrate
specificity (clone V2HS_94072, OpenBiosystems) [30]. Silencing
of UPIIIa gene expression was confirmed by real-time analysis,
and expression was reduced approximately 99% (Thumbikat et
al., manuscript in review). COS-7 cells and 5637 cells were used
for heterologous expression of uroplakins and were cultured in
DMEM containing 10% fetal bovine serum. Urothelial biomi-
metics cultures were generated by organotypic raft culture as
previously described [31].
Culturing of PD07i cells for immunofluorescence
PDO7i cells were suspended (1610
5 cells/ml) in a complete
bladder urothelium culture medium (FAD medium): 1:1 mixture
of DME and Ham’s FI2 medium, containing 10% FCS,
hydrocortisone (0.5 mg/ml), cholera toxin (5 ng/ml), insulin
(5 ug/ml), epidermal growth factor (15 ng/ml) [33]. 2610
5 cells
were seeded into upper chamber of a 24-mm Transwell with 3 ml
of FAD medium in the lower chamber. Culture medium was
changed regularly every 3 days (3 ml in the basolateral chamber
and 2 ml in the apical chamber). Cells were fixed at post-
confluence day-5 with fresh prepared 4% paraformaldehyde in
PBS pH 7.4 at 25uC for 15 min before immunostaining.
Uroplakin immunostaining
For single uroplakin immunostaining, cells were fixed and
incubated at 4uC overnight with anti-UPIa, Ib, II, and IIIa
antisera 1:200 diluted in 1% fish skin gelatin in PBS (pH 7.4). The
primary antibodies were detected with an Alexa Fluor 488-
conjugated donkey anti—-rabbit IgG (Cat# A-21206, Invitrogen,
Carlsbad, CA) in PBS (pH 7.4) with 1% FSG fish skin gelatin.
Cells were also incubated with 1 ug/ml propidium iodide (Cat #
537059, Calbiochem, San Diego, CA) at 25uC for 5 min for
nuclear staining. For uroplakin double staining, monovalent Fab
fragment of rhodamine-conjugated donkey anti-rabbit IgG (Cat#
711-297-003, Jackson Immunoresearch lab, West Grove, PA) was
used for detecting and blocking of double labeling of rabbit anti-
UPIa, and Ib antisera according to http://www.jacksonimmuno.
com/technical/fab-blok.asp. Fixed cells were first stained with
rabbit anti-uroplakins Ia, or Ib antisera, respectively, followed by
detecting and blocking with a monovalent Fab fragment of
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were briefly fixed for 15 min with 4% paraformaldehyde in PBS
(pH 7.4), and after 15 min neutralized using 100 mM NH4Cl in
PBS (pH 7.4), samples were double stained with anti-UPII or
UPIIIa rabbit antisera, and finally detected using the Alexa Fluor
488 conjugated donkey anti-rabbit IgG.
Uroplakins and FimH double staining
Fixed cells were incubated for 1 hr at 25uC in a TBS+ buffer
(150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2, 50 mM Tris-Cl
pH 7.4) with 1% fish skin gelatin, 10 ug/ml of biotinylated FimH/
C, and rabbit anti-uroplakin Ia, Ib, II, and IIIa antisera (1:200
dilution). The biotinylated FimH/C and anti-uroplakins antibod-
ies were detected using FITC-conjugated streptavidin and Alexa
Fluor 594-conjugated donkey anti-rabbit IgG (Cat# A21207,
Invitrogen, Carlsbad, CA), respectively.
Uroplakin immunoblotting
0.1 ug of bovine or human AUM proteins or 10 ng of
biotinylated FimH/C were resolved electrophoretically by 17%
SDS-PAGE and transferred onto a nitrocellulose membrane
(Cat# 162-0112, Bio-Rad, Hercules, CA). The individual
uroplakins were incubate with rabbit antisera against UPIa, Ib,
II, and IIIa, and followed by of 1 mg/ml horseradish peroxidase
(HRP)-labeled goat anti-rabbit IgG (Cat# A8275, Sigma, St.
Louis, MO). The biotinylated FimH/C was detected directly by
HRP-labeled streptavidin (Cat# S5512, Sigma, St. Louis, MO).
Detection of UPIIIa phosphorylation
PDO7i cells (5610
6) were incubated with 10 mg/ml FimCH for
15-30 minutes in culture medium followed by lysis in modified
RIPA buffer. Lysates were precleared with protein A sepharose
beads (Santa Cruz Biotechnology) for 90 minutes, followed by
addition of anti-human UPIIIa polyclonal antibody (rabbit
antibody raised against the human UPIIIa peptide
QTLWSDPIRTNQL; Invitrogen) and immunoprecipitation of
the complex with protein A sepharose. Eluted proteins were
fractionated on 4–15% SDS-polyacrylamide gels and transferred
to Immobilon-P membrane (Millipore). Blots were probed with
anti-phosphotyrosine or anti-phosphothreonine antibodies (Cell
Signaling Technologies, P-Tyr-100 monoclonal and P-Thr-
polyclonal respectively) and imaged by chemiluminescence.
Detection of intracellular calcium
Intracellular calcium ([Ca
2+]i) was quantified in fura-2/AM-
loaded PDO7i or COS 7 cells exposed to 10 mg/ml FimCH by
video fluorescence imaging [57]. Briefly, cells grown on cham-
bered coverslips were rinsed in modified Hank’s balanced salts
(HBSS) and incubated for 30 minutes in 5 mM fura-2/AM. The
cells were then washed in modified HBSS and monitored at
520 nm after excitation at 340 nm (bound Ca
2+) and 380 nm (free
Ca
2+) using a 206 water immersion lens. Fluorescence was
analyzed from at least 30 cells in each experiment using MetaFluor
software (Universal Imaging Corporation) from regions of interest
after correction for system background, shading errors, and
autofluorescence of unloaded cells. [Ca
2+]i was calculated by the
ratio method [58]. Inhibitors 2-aminoethoxydiphenyl borate,
nifidipine and CK2 inhibitor 1 (TBB) were from Calbiochem,
and wortmannin, EGTA and BAPTA-AM were from Sigma. For
inhibitor experiments, cells were pre-incubated with drugs or
vehicle for 30 minutes at 25uC prior to FimCH exposure. [Ca
2+]i
elevation was calculated by subtracting the baseline [Ca
2+]i from
the maximal calcium value.
Site-directed mutagenesis and expression of uroplakins
The human UPIb and UPIIIa cDNA clones were kind gifts
from Dr. Jennifer Southgate. Individual uroplakin cDNAs were
cloned into the multiple-cloning site of pDONR followed by
transfer into the pAd/CMV/V5-DEST adenoviral vector with
Gateway technology (Invitrogen). The resulting plasmids were
linearized by digestion with PmeI and transfected into HEK 293
cells. Recombinant adenoviruses were titered and stored at 270uC
until use. UPIIIa variant adenoviruses were generated (T244A,
T244E, S282A, S282E, and Y266F) by site-directed mutagenesis of
the wild type pAd/CMV/UP3 sequence. COS-7 cells and 5637
cells were infected with uroplakin adenoviruses for 4 h
(MOI=100) and incubated for 20 hours before experiments.
Affinity purification of UPIIIa antibodies
Anti-AUM antiserum was affinity purified to yield a UPIII-
specific ‘‘P3’’ fraction as previously described [59]. Briefly, UPIIIa
peptide (S87 to K101) was immobilized on nitrocellulose.
Following blocking of the filter with BSA, the filter was incubated
with anti-AUM for 1 h at room temperature, and bound
antibodies were then eluted with 50 mM diethylamine (pH 11.5)
and immediately neutralized with 1M Tris-HCl (pH 7.4).
In vitro phosphorylation of UPIIIa C-terminus
The DNA sequence encoding the C-terminal 52 amino acids of
UP3 (UP3C) was cloned into the Sgf I and Pme I sites of the
glutathione-S-transferase (GST) vector pFN2A (Promega). UP3C-
GST fusion protein was purified from E. coli strain BL21 using
standard techniques. Casein kinase II-mediated phosphorylation
of the C-terminal domain of uroplakin IIIa was performed using
standard protocols [60]. Briefly, kinase reactions were performed
in 20 mM Tris-HCl pH7.5, 150 mM KCl, 5 mM MgCl2, and
500 mM DTT containing 20 mCi
32P-ATP (3000 mCi/mmol),
cold ATP to 5 mM, and 50 U recombinant human recombinant
CK2 (Calbiochem 218701). Some reactions also included 10 mM
CK2 inhibitor TBB (Calbiochem 21708). Reactions were
incubated at 30uC for 10 min before termination with SDS
loading dye and electrophoresis through 10% polyacrylamide.
RNA interference of Casein Kinase 2
PD07i cells were transfected overnight using Lipofectamine
2000 (Invitrogen) with a total of 200 pmol/well (6-well plates) or
40 pmol/well (24-well plates and chambered coverslips) of
combination of equal amounts of each dsRNA duplex from the
CSNK2A1 Validated Stealth
TM RNAi Duopak (Invitrogen) or the
equivalent amount of Stealth
TM RNAi Negative Control Med GC
duplex as a negative control. The following day, the transfection
media was removed and fresh culture media was added to the
cells. Forty-eight hours following transfection, the cells were used
to determine intracellular invasion efficiency, caspase 3/7
activation following infection with NU14 or [Ca
2+]I elevation
following FimCH treatment.
Bacterial adherence and invasion
PD07i cells were infected with NU14 (MOI 10) and centrifuged
twice at 6006g for 2.5 min. Infected cultures were incubated at
37uC for 2 h. To measure adherence, cells were washed 4 times
with PBS and incubated with 0.05% trypsin/0.1%Triton X-100
for 10 minutes to lyse cells. Lysates were harvested, plated on LB-
agar containing appropriate selection, and colonies were counted
to quantify bound bacteria. To measure invasion, cells were
infected and washed as above before incubating in 100 mg/ml
gentamicin for 30 minutes at 37uC and plating lysates as described
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presence of inhibitor or vehicle and incubated at 37uC 1 h and
then changing to inhibitor-free media for 1 h. Mice were infected
via transurethral catheter with 10 ml of bacterial suspension
containing 10
8 CFU [40] containing 10 mM TBB or vehicle. After
2 h, animals were sacrificed and opened bladders were incubated
in PBS containing 100 mg/ml gentamicin for 30 minutes at 37uC
before rinsing and plating tissue homogenates.
Fluorescence microscopy for UPEC detection
To detect intracellular UPEC, PD07i cells were seeded into 4-
well chambered slides and grown to confluence. Cells were
infected at an MOI 100 with NU14/pcomGFP [61] and
incubated at 37uC 2 h. To stain extracellular bacteria, cells were
incubated with biotinylated anti-E. coli antibody (Abcam) in
Epilife/1% BSA at 37uC. Cells were washed and fixed in 1% PFA
then blocked in PBS/1% BSA before incubating with Streptavi-
din-AlexaFluor 594 (Invitrogen). Each step occurred for 30 min-
utes at 25uC and slides were washed three times with PBS between
each step. Images were acquired with OpenLab (Improvision)
using a 636 HCX PlanApo objective on a Leica DM-IRE2
microscope outfitted with an OCRA2 camera (Hamamatsu), and
fluorescent channels were merged with DIC imaging; curves
demarking the nucleus and cell margins were added to aid
interpretation.
For detection of uroplakin expression, COS-7 cells were
infected with recombinant adenoviruses encoding human uropla-
kins (MOI 100). The following day, cells were fixed for 15 min. at
25uC with freshly prepared 4% paraformaldehyde in PBS pH 7.4.
Cells were then rinsed and quenched with 10 mM glycine in PBS
pH 7.4 at 25uC for 10 min. The cells were then incubated with
3% bovine serum albumin in PBS pH 7.4 with affinity purified
rabbit anti-UPIII (P3 fraction) and AU1 (mAb) at 25uC for 1 h,
rinsed three times with PBS pH7.4 at 25uC, and incubated 1 h
with Alexa Fluor 594 goat anti—rabbit IgG (Invitrogen A-11037)
and Alexa Fluor 488 goat anti—mouse IgG (Invitrogen A-11029).
Images were collected with a Zeiss Axioskop 2 fluorescent
microscopy by AxioVision 4.5 software.
Measurement of apoptosis
Apoptosis in cultured cells was assayed using the Annexin-V-
FLUOS kit (Roche Diagnostics) as previously described [30].
Annexin-positive cells were quantified by examining independent
fields in 3 separate wells of a 12-well plate. For each field,
brightfield and fluorescent images were captured. Total cells
(brightfield) and apoptotic cells (fluorescent) were quantified
manually in each image. Caspase 3/7 activity in urothelial cell
cultures was determined using the Apo-One Homogeneous
Caspase 3/7 Assay (Promega). Briefly, PD07siLuciferase and
PD07siUPIII cultures were grown in 15 cm plates and treated
with 15 ml of media containing either NU14 or NU14-1 for
3 hours (MOI 500). Dishes were washed, harvested by scraping,
and resuspended in 500 ml of the manufacturer’s recommended
hypotonic lysis buffer. Induction of caspase 3/7 activity in each
homogenate was normalized both to the levels of untreated control
samples of each cell line and to total protein concentration as
determined by BCA assay (Pierce Chemical). Apoptosis in bladder
sections and urothelial biomemetics was detected using the
TUNEL reaction (Roche) as previously described [30].
Statistical analyses
Data were analyzed using Prism version 4.0 (GraphPad) and
presented as mean6SEM. The statistical significance of differ-
ences between groups was calculated using Student’s two-tailed t
test or Mann-Whitney test for two groups or one-way ANOVA
with Dunnett’s post-test comparison. P,0.05 was considered
significant.
Supporting Information
Figure S1 Detecting and blocking of rabbit antisera with a
monovalent Fab fragment of rhodamine-conjugated donkey anti-
rabbit IgG. (A) Surface-expressed uroplakins were reacted with
monospecific rabbit antisera against UPIa, followed by Alexa
Fluor 488-conjugated donkey anti-rabbit IgG (a–c), or with a
monovalent Fab fragment of rhodamine-conjugated donkey anti-
rabbit IgG (d–f), or first with monovalent Fab fragments of
rhodamine-conjugated donkey anti-rabbit IgG, and sequentially
with Alexa Fluor 488-conjugated donkey anti-rabbit IgG (g–i). (B)
10 ng of biotinylated FimH/C complex was detected using HRP-
labeled streptavidin. FimH (31 k-Dd) and FimC (28 k-Da) were
both biotinylated.
Found at: doi:10.1371/journal.ppat.1000415.s001 (5.09 MB TIF)
Figure S2 UPEC bacterial strains can induce phosphorylation of
UPIIIa in a FimH-dependent manner. PD07i cultures were
treated for 30 minutes with NU14 or NU14-1 at an MOI of 500
or treated with PBS. Cells were washed in cold PBS followed by
lysis in modified RIPA buffer. UPIIIa was immunoprecipitated
and equal amounts of protein were separated using SDS-PAGE
followed by immunoblotting using an anti-phosphothreonine
antibody. UPIIIa from NU14-treated cells was observed to be
phosphorylated to a higher degree (Lane-2) than NU14-1 (Lane-3)
or saline-treated cells (Lane 1).
Found at: doi:10.1371/journal.ppat.1000415.s002 (0.61 MB TIF)
Figure S3 Affinity purification of UPIIIa-specific antibodies.
Purified bovine AUM protein (bAUM) was separated by SDS
PAGE and probed with Anti-AUM serum (A). Immunoblotting
with anti-AUM serum recognized a family of bands including
UPIII (migrating at approximately 45 kD) and UPIb. (B)
Following stripping of the blot, AUM proteins were probed with
affinity-purified, UPIII-specific antibodies (P3 fraction). P3
antibodies recognized only the family of bands corresponding to
UPIIIa in various states of glycosylation.
Found at: doi:10.1371/journal.ppat.1000415.s003 (0.65 MB TIF)
Figure S4 UPIIIa variants are expressed on the cell surface.
COS7 cells were co-infected with recombinant adenoviruses
encoding UPIb and a variant of UPIb, followed by imaging by
immunofluorescence. (A–D) COS7 cells expressing the UPIIIa
variant T244A and stained with affinity-purified UPIII antibody
fraction P3 (A, red channel), UPIIIa monoclonal antibody AU1 (B,
green channel), DAPI (C, blue channel), or all channels combined
(D). (E) COS7 cells expressing the UPIIIa variant S282A and
stained with affinity-purified UPIIIa antibody fraction P3 (red
channel), UPIIIa monoclonal antibody AU1 (green channel), and
DAPI (blue). (F) COS7 cells expressing the UPIIIa variant T244E
and stained with affinity-purified UPIIIa antibody fraction P3 (red
channel), UPIIIa monoclonal antibody AU1 (green channel), and
DAPI (blue). (G) COS7 cells expressing the UPIIIa variant S282E
and stained with affinity-purified UPIIIa antibody fraction P3 (red
channel), UPIIIa monoclonal antibody AU1 (green channel), and
DAPI (blue). (H) COS7 cells expressing the UPIIIa variant Y266F
and stained with affinity-purified UPIIIa antibody fraction P3 (red
channel), UPIIIa monoclonal antibody AU1 (green channel), and
DAPI (blue). Arrows indicate margins of cells where surface
UPIIIa expression is evident.
Found at: doi:10.1371/journal.ppat.1000415.s004 (3.66 MB TIF)
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PD07siTNFR2 or PD07siUPIII cultures were stimulated with
10 ng/ml IL-1b or infected with NU14 (MOI 500) for 4 hours at
37uC. CXCL-8 was quantified in culture supernatants by ELISA
(Pharmingen). No significant differences in CXCL-8 secretion
were observed.
Found at: doi:10.1371/journal.ppat.1000415.s005 (0.10 MB TIF)
Figure S6 CK2 mRNA expression is reduced using RNA
interference. PD07i cultures were transfected with CK2 siRNA or
a non-specific control siRNA. Total RNA was purified and
primers for human CK2 (forward 59-agg cag gaa gaa agg aag gaa-
39, reverse 59-aga cac act tcc aca aga gcc act-39) were used to
quantify CK2 mRNA expression by real-time PCR. Results were
expressed as relative fold change where Ct values were normalized
first to the ribosomal subunit L19 mRNA and an untreated
control. Analyses were performed using the DDCt method.
Found at: doi:10.1371/journal.ppat.1000415.s006 (0.07 MB TIF)
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